- Funding to support pivotal testing of non-surgical permanent contraception solution FemBloc™ -
- IDE approval granted by FDA for U.S. clinical trial of FemBloc; study to start early 2017 -
ATLANTA, Dec 16 (Bernama-GLOBE NEWSWIRE) -- Femasys Inc., a developer of innovative medical devices for the women's healthcare market, today announced that it has closed $40 million in Series C financing. The transaction was arranged by Salem Partners, a Los Angeles-based investment bank which also participated as a principal investor. The Series C syndicate included multiple institutional investors, family offices and a multibillion-dollar global medical device company. The funding will be used primarily to support the pivotal testing of FemBloc™, the Company's revolutionary, non-surgical permanent contraception solution. Femasys designed FemBloc to provide women with the first non-surgical permanent contraceptive option delivered exclusively in the physician's office.
- IDE approval granted by FDA for U.S. clinical trial of FemBloc; study to start early 2017 -
ATLANTA, Dec 16 (Bernama-GLOBE NEWSWIRE) -- Femasys Inc., a developer of innovative medical devices for the women's healthcare market, today announced that it has closed $40 million in Series C financing. The transaction was arranged by Salem Partners, a Los Angeles-based investment bank which also participated as a principal investor. The Series C syndicate included multiple institutional investors, family offices and a multibillion-dollar global medical device company. The funding will be used primarily to support the pivotal testing of FemBloc™, the Company's revolutionary, non-surgical permanent contraception solution. Femasys designed FemBloc to provide women with the first non-surgical permanent contraceptive option delivered exclusively in the physician's office.
No comments:
Post a Comment